Clinical Trial Update: A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss [Phase 3]

View source ↗

Summary

A Phase III study comparing drug 601 to ranibizumab for vision loss due to branch retinal vein occlusion has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Branch Retinal Vein Occlusion

Drugs mentioned

• 601
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Conditions: Branch Retinal Vein Occlusion | Phase 3 | Status: COMPLETED